Home / Conditions / Type 2 Diabetes (page 9)

Type 2 Diabetes

Type 2 Diabetes Research and News: Type 2 diabetes is a metabolic disorder. Though most commonly diagnosed in the elderly, younger adults and even children are increasingly subject to the disease. 9.4% of the US population has Type 2 diabetes or about 30 million Americans. Approximately 95% of all adults diagnosed with diabetes have Type 2. New tools, techniques and treatments can help you improve outcomes for your Type 2 diabetes patients.

Use of SGLT-2 inhibitors As Adjunct to Insulin In People with Type 1 Diabetes

Jul 8, 2017 Type 1 Diabetes, Type 2 Diabetes, Articles, Insulin Therapy Center, SGLT-2 Therapy Center

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

Glucose Self-Monitoring For Non-Insulin Using Patients Did Not Improve Control

Jul 1, 2017 Type 2 Diabetes, Articles, Blood Glucose Control

The value of self-monitoring of blood glucose (SMBG) levels in patients with non-insulin-treated type 2 diabetes has been debated over the years.

Liraglutide Gets FDA Indication For Reducing CVD Risk, But Not So Fast

Jun 24, 2017 Type 2 Diabetes, Cardiology, Articles

The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in excess cardiovascular risk.

ADA: Basal Oral Insulin Tablet Reduces Fasting Blood Glucose and HbA1c Levels Similar to Insulin Glargine in Patients with Type 2

Jun 24, 2017 Type 2 Diabetes, Articles, Blood Glucose Control, Insulin Therapy Center

However, in 2016, Novo Nordisk halted the development of their basal oral insulin tablet.

ADA: Degludec Deemed Non-Inferior to Glargine Regarding Cardiovascular Safety in High Risk Patients with Type 2

Jun 17, 2017 Type 2 Diabetes, Cardiology, Insulin Therapy Center

The DEVOTE trial compared cardiovascular safety in two basal insulins; insulin degludec was found to have additional benefits.

ADA: Praluent® (alirocumab) Associated with Reducing Risk of Cardiovascular Disease in Type 2 Diabetes

Jun 17, 2017 Type 2 Diabetes, Cardiology, Articles

Results from two ODYSSEY studies indicate the favorable lipid lowering effects of Alirocumab, a PCSK9 inhibitor, in type 2 diabetes patients can potentially reduce the risk of cardiovascular disease.